The company received notice earlier this month of an opinion rendered by the Medicines and Healthcare products Regulatory Authority (MHRA) in the United Kingdom related to the classification of the OxySure Model 615 as a medical device. An opinion of this nature by a competent authority is a key step in the CE Marking process.
“We are pleased with this opinion from MHRA,” commented Mark Gilmore, Managing Partner of Aero Healthcare, OxySure’s partner in the United Kingdom. Gilmore, who oversees the CE Marking process, added, “In addition, we have already substantially completed our technical file for the CE Marking process and we plan to move forward post haste with our notified body on the next steps of the CE Marking of OxySure.”
The CE marking will enable the free movement and sale of products within the European market. With the marking, OxySure’s approved products can be sold in approximately 31 countries in the European Economic Area (EEA), comprising the 28 Member States of the European Union and the European Free Trade Association (EFTA) countries of Iceland, Norway, and Liechtenstein. As of January 1, 2012, the population of the European Union was approximately 503.5 million people.
For more information, visit www.OxySure.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment